Novartis Venture Fund

Novartis Venture Fund's primary focus is on the development of novel therapeutics and platforms. They balance the therapeutic focus with investments in medical devices, diagnostics, or drug delivery systems. In their investments, they look for unmet needs and clinical impact, novel proprietary science, an understanding of mechanism, management and board experience, and capital efficiency in the program.

Novartis Venture Fund prefers to have their initial investment at the early stage to build the company and follow with additional investment in pace with the company's progress. Their approach involves larger focused investments, with anticipation of total investments up to USD 30 to 50 million per company over its life, but it can be as little as 100,000 USD to get started. They plan to increase their activities to lead or co-lead deals further and remain open to participating in larger syndicates.

Novartis Venture Fund, established in 1996 and headquartered in Switzerland, Europe., specializes in Late Stage Venture, Early Stage Venture, Seed, Private Equity investments across Biotechnology, Health Care, Pharmaceutical, Financial Services, Venture Capital, Finance, Medical, FinTech, Business Development, Education. The organization boasts a portfolio of 256 investments, with an average round size of $33.5M and 71 successful exits. Their recent investments include Sirtris Pharmaceuticals, Skyline Ventures, Three Arch Partners, TVM Capital, Bessemer Venture Partners. The highest investment round they participated in was $829.5B. Among their most notable exits are Sirtris Pharmaceuticals and Skyline Ventures. Explore their portfolio in detail, see who is connected to them, and find their contact information on our platform.